Bionyra Pharma
Summary active Updated Jun 22, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Bionyra Pharma is a France-based clinical-stage biotech launched in 2026 to develop next-generation biologics for immune-mediated inflammatory diseases 1. The company was co-founded by Frédéric Marrache, formerly head of immunology R&D at Sanofi, together with Sofinnova Partners 2. Its pipeline is built around BYN-002 and additional licensed monoclonal and bispecific antibody assets 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-22 | Series A | $165M (€143M) | Sofinnova Partners, Jeito Capital | Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, Apollo Health Ventures 12345 |
The Series A was described as oversubscribed in the company’s launch press release 1.
What Investors Say
“You’re clearly on the next generation of biologics, so here are these very established lines where we will try to beat the efficacy ceiling.”
— Mehdi Ainouche, Partner at Jeito Capital 2
“When we co-founded Bionyra with Frédéric, our conviction in both the company and his leadership was grounded in his deep expertise in immune and inflammatory diseases. Today, that conviction is reflected in a $165 million oversubscribed round backed by an exceptional syndicate of investors who share our belief in this pipeline and the team behind it.”
— Anta Gkelou, Partner at Sofinnova Partners 4
“Bionyra embodies the type of company we are committed to backing at Jeito: a highly differentiated, science-driven platform.”
— Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital 5
What Founders Say
“The biotech space does have an edge here when it comes to getting things done.”
— Frédéric Marrache, Co-Founder & CEO 2
Sources
-
Bionyra Pharma press release via BusinessWire, “Bionyra Pharma Launches with $165 million Oversubscribed Series A,” June 22, 2026. Accessed June 2026. https://www.businesswire.com/news/home/20260622319137/en/Bionyra-Pharma-Launches-with-$165-million-Oversubscribed-Series-A-to-Advance-Clinical-Stage-Pipeline-of-Next-Generation-Biologics-for-Immune-Mediated-Inflammatory-Diseases↩↩↩
-
BioPharma Dive, “Bionyra brings in $165M for next-generation immune drugs,” June 22, 2026. Accessed June 2026. https://www.biopharmadive.com/news/bionyra-immune-drug-startup-sofinnova-jeito/823296/↩↩↩↩↩
-
BeBeez International, “France’s Bionyra Pharma launches with €143 million Series A to advance inflammatory disease biologics,” June 22, 2026. Accessed June 2026. https://bebeez.eu/2026/06/22/frances-bionyra-pharma-launches-with-e143-million-series-a-to-advance-inflammatory-disease-biologics/↩
-
Sofinnova Partners, “Bionyra Pharma Launches with $165 million Oversubscribed Series A,” June 22, 2026. Accessed June 2026. https://sofinnovapartners.com/news/bionyra-pharma-launches-with-usd165-million-oversubscribed-series-a-to-advance-clinical-stage-pipeline-of-next-generation-biologics-for-immune-mediated-inflammatory-diseases↩↩
-
Jeito Capital, “Jeito Capital co-leads a $165 million oversubscribed Series A financing in Bionyra Pharma,” June 22, 2026. Accessed June 2026. https://www.jeito.life/en/jeito-capital-co-leads-usd-165-million-oversubscribed-series-a-financing-bionyra-pharma/↩↩